BIOPTIC helps pharma teams and investors evaluate drug assets, track competitors, and plan product launches. Our AI agents gather and organize the evidence, and pharma experts review the findings.
AI for the commercial side of pharma
Work
How we can help
Choose a service below or bring us a specific research question. We agree on the scope, deliverables, and timeline before work begins.
"Identify Phase 2 oncology drug candidates in China that meet our scientific and licensing criteria."
"Compare GLP-1 development programs by trial design, stage, and upcoming milestones."
"Map the ALS care pathway in Germany, Japan, and China."
Platform
How we answer your research question
Our platform combines pharma data sources with AI agents that search in parallel. The agents organize findings and supporting evidence for expert review. We test the system on pharma research tasks and publish the results.
.avif)
Agents search trial registries, patents, publications, company disclosures, and Chinese-language sources.
Review the findings, supporting sources, and questions that need further investigation.
.avif)
Receive a structured report. For monitoring projects, we continue tracking changes on an agreed schedule.
Benchmarks
See how we evaluate BIOPTIC
Our published studies describe the research tasks, AI systems, and scoring methods used to evaluate BIOPTIC. Read the results and limitations of each study.
From manual and reactive to always-on
BIOPTIC AI Agents
Legacy CI — in-house or consultancy
Global vision
100+ feeds in 40+ languages, in real time
Blind spots
Missed programs and late updates
Pharma-grade accuracy
Multi-model cross-check, expert peer review
Errors
Human error plus LLM hallucination
Insight in hours
Thousands of agents reading in parallel
Slow time-to-insight
Days and weeks to a decision
Humans decide
80% of the time back for the decision itself
Humans extract data
50% collecting, 30% cleaning, 20% deciding
A landscape that stays live
It keeps updating and tells you what moved
A deliverable that ages
A deck that is stale the week after it lands
Asset Scouting: agent performance
DOMAIN-SPECIFIC
BIOPTIC
80%
CLAUDE FAMILY
Opus 5 — high
38%
Opus 5 — xhigh
35%
Opus 5 — max
46%
Fable 5.1
Blocked — bio-safety filter
CODEX (GPT) FAMILY
GPT-5.6-Sol — medium
51%
GPT-5.6-Sol — high
54%
GPT-6-Astra — high
50%
Reasoning effort shown beside each model. GPT models run via Codex. Fable 5.1 produced no score: refused at the bio-safety filter.
Company
Pharma expertise is part of the process
Our scientists and pharma professionals review the analysis before delivery. They check the evidence, flag gaps, and assess whether the findings answer your question.
Our people came from
Published research
Read our studies on drug discovery, asset scouting, and competitive landscape analysis.